Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor

Br J Pharmacol. 2012 Jun;166(3):1151-68. doi: 10.1111/j.1476-5381.2012.01833.x.

Abstract

Background and purpose: Caffeic acid phenethyl ester (CAPE) is a component of honey bee propolis that can induce expression of haem oxygenase-1 (HO-1). Because HO-1 induction has been suggested to protect dopaminergic neurons in the substantia nigra, we examined the effect of CAPE in experimental models of dopaminergic neurodegeneration.

Experimental approach: Neuroprotective effect of CAPE was investigated in rat organotypic midbrain slice cultures and in vivo, using a mouse model of dopaminergic neurodegeneration induced by intranigral injection of LPS and intrastriatal injection of 6-hydroxydopamine.

Key results: CAPE protected dopaminergic neurons in slice cultures from IFN-γ/LPS-induced injury. The effect of CAPE was inhibited by zinc protoporphyrin IX, an HO-1 inhibitor, and by neutralizing antibody against brain-derived neurotrophic factor (BDNF). A p38 MAPK inhibitor SB203580 prevented activation of NF-E2-related factor 2, attenuated increased expression of HO-1 and BDNF, and blocked the neuroprotective actions of CAPE. In the LPS-injected mouse model, daily intraperitoneal administration of CAPE protected dopaminergic neurons, up-regulated HO-1 and BDNF, and reduced the increase of activated microglia/macrophages. Neuroprotective effects of CAPE against LPS-induced injury was prevented by zinc protoporphyrin IX or anti-BDNF antibody. CAPE protected dopaminergic neurons and alleviated methamphetamine-induced rotational behaviour also in 6-hydroxydopamine hemiparkinsonian mice.

Conclusion and implications: CAPE is a novel type of neuroprotective agent whose actions are mediated by both HO-1 and BDNF. These findings may provide novel clues to develop neuroprotective agents for treatment of neurodegenerative disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Caffeic Acids / pharmacology*
  • Caffeic Acids / therapeutic use
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / enzymology
  • Dopaminergic Neurons / metabolism
  • Enzyme Induction
  • Heme Oxygenase-1 / antagonists & inhibitors
  • Heme Oxygenase-1 / biosynthesis*
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Nitric Oxide / metabolism
  • Parkinsonian Disorders / drug therapy
  • Parkinsonian Disorders / enzymology
  • Parkinsonian Disorders / metabolism
  • Phenylethyl Alcohol / analogs & derivatives
  • Rats
  • Rats, Wistar
  • Substantia Nigra / drug effects*
  • Substantia Nigra / enzymology
  • Substantia Nigra / metabolism

Substances

  • Brain-Derived Neurotrophic Factor
  • Caffeic Acids
  • Neuroprotective Agents
  • Nitric Oxide
  • Heme Oxygenase-1
  • caffeic acid phenethyl ester
  • Phenylethyl Alcohol